Loading clinical trials...

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED | Clinical Trials | Clareo Health

RECRUITINGPHASE2

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With Persistent Corneal Epithelial Defects (NEXPEDE-1)

NCT05966493•Glaukos Corporation

View on ClinicalTrials.gov

Summary

This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.

Detailed Description

This study is a randomized, multicenter, double-masked, vehicle-controlled study to evaluate the safety and efficacy of NEXAGON (lufepirsen ophthalmic gel) in subjects with persistent corneal epithelial defects (PCED). The study will enroll subjects who will complete a Screening Period, Treatment Period (up to 8 weeks) and Follow-up Period (4 weeks). Those subjects whose defect has not re-epithelialized by the completion of the Treatment Period or who achieved re-epithelialization but failed to maintain re-epithelialization for 28 days after treatment completion (durability) are eligible to enter the NEXAGON Open-label Treatment Period for an additional 8 weeks.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Have a PCED that is at least 2 weeks in duration and refractory to one or more conventional non-surgical standard of care (SOC) treatments
•2. Have no clinical evidence of improvement in the PCED within 2 weeks prior to randomization despite the use of non-surgical SOC treatment
•3. Subject must provide written informed consent (or assent)
•4. Subjects with childbearing potential must be 1-year postmenopausal, surgically sterilized, or have a negative urine pregnancy test

Exclusion Criteria

•1. Have a known ocular infection that is deemed to be active requiring therapeutic intervention
•2. Present with a corneal surface defect in either eye that is directly attributed to an infectious etiology (bacterial, viral, fungal and/or protozoal) that has not fully resolved and/or treatment has not been completed
•3. Present with evidence of corneal ulceration/melting involving the posterior third of the stroma and/or perforation in either eye
•4. Have a blepharitis or meibomian gland disease in the study eye that is deemed to be clinically relevant and/or active
•5. Have a history of ocular surgery or any ocular procedure(s) not meeting the designated washout time
•6. Have any other ocular disease requiring topical ocular medication in the affected eye
•7. Have a presence or history of any ocular or systemic disorder or condition that could interfere the safety or efficacy of the study treatment, or the interpretation of the study results
•8. Have a known hypersensitivity to one of the components of the study or procedural medications (e.g., NEXAGON, fluorescein)
•9. Participated in an interventional clinical drug or device trial within 28 days prior to Day 1
•10. Use of the medications presented in the protocol that are prohibited in the study.

Locations (28)

Glaukos Investigative Site

Dothan, Alabama, United States

Glaukos Investigative Site

Petaluma, California, United States

Glaukos Investigative Site

Torrance, California, United States

Glaukos Investigative Site

Colorado Springs, Colorado, United States

Glaukos Investigative Site

Grand Junction, Colorado, United States

Glaukos Investigative Site

Bradenton, Florida, United States

Glaukos Investigative Site

Fort Myers, Florida, United States

Glaukos Investigative Site

South Miami, Florida, United States

Glaukos Investigative Site

Atlanta, Georgia, United States

Glaukos Investigative Site

Carmel, Indiana, United States

Key Dates

Start Date

August 17, 2023

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

July 24, 2025

Enrollment

ESTIMATED participants

Conditions

Persistent Corneal Epithelial Defect

Interventions

lufepirsen high dose

DRUG

Vehicle

DRUG

lufepirsen low dose

DRUG

Contacts

Study Director

CONTACT

949-739-8749 ClinicalResearch@Glaukos.com

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

NCT06919081

Persistent Corneal Epithelial DefectCorneal Epithelial Disorders

View study

COMPLETEDPHASE2

A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects

NCT05436288

Persistent Corneal Epithelial Defect

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Inclusion Criteria

Exclusion Criteria

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects

Platelet Rich Plasma in Corneal Surface Diseases

Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers

Autologous Platelet Lysate in Corneal Epithelial Defects